UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response

Invasion and Metastasis

Volumn 18, Issue 4, 1998, Pages 209-218

  Kruger, Erwin A ^a   Blagosklonny, Mikhail V ^a   Dixon, Shannon C ^a   Figg, William D ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

7 Hydroxystaurosporine; Angiogenesis; Cancer; Therapy; Vascularization

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANGIOGENESIS INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; VASCULAR RING;

EID: 0032240610     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024514     Document Type: Article

References (44)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31.
2. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
3. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16:4604-4613.
4. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
5. Ryan HE, Lo J, Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-3015.
6. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L: A hypoxiaresponsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995;182:1683-1693.
7. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
8. Kim KJ, Li B, Winer J, Armanini M, Gillett N et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
9. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA et al: Angiostatin: A novel angiogenesis inhibitor that mediates the supression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
10. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 1991;13:31-36.
11. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
12. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD et al: Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-992.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
14. Panek RL, Lu GH, Dahring TK, Batley BL, Connolly C et al: In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J Pharmacol Exp Ther 1998;286:569-577.
15. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272:27509-27512.
16. Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9: 963-969.
17. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ: Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-3440.
18. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ et al: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98:2018-2026.
19. Kent KC, Mii S, Harrington EO, Chang JD, Mallette S, Ware JA: Requirement for protein kinase C activation in basic fibroblast growth factor-induced human endothelial cell proliferation. Circ Res 1995;77: 231-238.
20. Seymour LW, Shoaibi MA, Martin A, Ahmed A, Elvin P et al: Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells. Lab Invest 1996;75:427-437.
21. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M: Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-4892.
22. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM et al: UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem 1998;273: 33455-33464.
23. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA: Apoptosis in 7-hydroxy staurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995;6:927-936.
24. Pollack IF, Kawecki S, Lazo JS: Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 1996;84: 1024-1032.
25. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/ Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57:1495-1501.
26. Courage C, Budworth J, Gescher A: Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation. Br J Cancer 1995;71:697-704.
27. Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O et al: In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs 1994;5: 336-342.
28. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-1834.
29. Salnikow K, An WG, Melillo G, Blagosklonny MV, Costa M: Nickel-induced transformation shifts the balance between HIF-1a and p53 transcription factors. Carcinogenesis, in press.
30. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature 1998;392:405-408.
31. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 1994;45:1207-1214.
32. Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A et al: Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999;43:205-212.
33. Wang GL, Semenza GL: Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood 1993;82: 3610-3615.
34. Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L: Functional requirement of the hypoxiaresponsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997; 272:12236-12243.
35. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L et al: Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996;97:469-476.
36. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N et al: Increased expression of hypoxia inducible factor-1 alpha in rat and human prostate cancer. Cancer Res 1998;58:5280-5284.
37. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD et al: Clinical pharmacology of UCN-01: initial observations and comparison to pre-clinical models. Cancer Chemother Pharmacol 1998;42:S54-S59.
38. Jones MK, Sarfeh IJ, Tarnawski AS: Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK. Biochem Biophys Res Commun 1998;249: 118-123.
39. Strohmeyer D: Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res 1999;19:1557-1561.
40. Fujioka T, Hasegawa M, Ogiu K, Matsushita Y, Sato M, Kubo T: Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J Urol 1996;155:1775-1778.
41. Zezula J, Sexl V, Hutter C, Karel A, Schutz W, Freissmuth M: The cyclin-dependent kinase inhibitor p21cip1 mediates the growth inhibitory effect of phorbol ester in human venous endothelial cells. J Biol Chem 1997;272:29967-29974.
42. Blagosklonny MV: The mitogen-activated protein kinase pathway mediates growth arrest or E1A-dependent apoptosis in SKBr3 human breast cancer cells. Int J Cancer 1998;78:511-517.
43. Harrington EO, Loffler J, Nelson PR, Kent KC, Simons M, Ware JA: Enhancement of migration by protein kinase C alpha and inhibition of proliferation and cell cycle progression by protein kinase C delta in capillary endothelial cells. J Biol Chem 1997;272:7390-7397.
44. Morris PB, Hida T, Blackshear PJ, Klintworth GK, Swain JL: Tumor-promoting phorbol esters induce angiogenesis in vivo. Am J Physiol 1988;254:C318-C322.